Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemotherapy Combined With Bevacizumab Followed by Niraparib Monotherapy in Newly Diagnostic Advanced Ovarian Cancer With HRD Positive : A Perspective, Multicenter, Single-arm Phase II Trial

NCT06141265 is registered in ClinicalTrials.gov with Peking University Cancer Hospital & Institute as lead sponsor.

NCT NCT06141265
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06141265 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemotherapy Combined With Bevacizumab Followed by Niraparib Monotherapy in Newly Diagnostic Advanced Ovarian Cancer With HRD Positive : A Perspective, Multicenter, Single-arm Phase II Trial
Lead sponsor
Peking University Cancer Hospital & Institute
Phase
Phase 2
Overall status
Recruiting
Start date
November 1, 2023
Completion date
December 31, 2028
Enrollment
116 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian, fallopian tube and primary peritoneal carcinoma